Biofrontera to present at Lytham Partners Fall 2025 Investor Conference.
ByAinvest
Friday, Sep 26, 2025 9:19 am ET1min read
BFRI--
The webcast presentation will take place at 1:15 p.m. ET on Tuesday, September 30, 2025. Investors can access the webcast through the conference website or directly via the provided link, with replay available after the event. The webcast can be accessed by visiting the conference home page at [https://lythampartners.com/fall2025/](https://lythampartners.com/fall2025/) or directly at [https://app.webinar.net/wWqPp4Yr0kD](https://app.webinar.net/wWqPp4Yr0kD).
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at [https://lythampartners.com/fall2025invreg/](https://lythampartners.com/fall2025invreg/).
Biofrontera Inc. focuses on the development and treatment of dermatological conditions, with a particular emphasis on Photodynamic Therapy (PDT). The company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of actinic keratosis (AK), pre-cancerous skin lesions, which may progress to invasive skin cancers. Additionally, Biofrontera conducts clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit [www.biofrontera-us.com](https://www.biofrontera-us.com) and follow Biofrontera on LinkedIn and X.
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
Biofrontera Inc. will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The webcast presentation will be available at 1:15 p.m. ET, and one-on-one meetings can be arranged by contacting Lytham Partners.
Biofrontera Inc. (NASDAQ: BFRI), a biopharmaceutical company specializing in dermatological products, has announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will deliver a webcast presentation at 1:15 p.m. ET and conduct one-on-one meetings with investors throughout the virtual event.The webcast presentation will take place at 1:15 p.m. ET on Tuesday, September 30, 2025. Investors can access the webcast through the conference website or directly via the provided link, with replay available after the event. The webcast can be accessed by visiting the conference home page at [https://lythampartners.com/fall2025/](https://lythampartners.com/fall2025/) or directly at [https://app.webinar.net/wWqPp4Yr0kD](https://app.webinar.net/wWqPp4Yr0kD).
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at [https://lythampartners.com/fall2025invreg/](https://lythampartners.com/fall2025invreg/).
Biofrontera Inc. focuses on the development and treatment of dermatological conditions, with a particular emphasis on Photodynamic Therapy (PDT). The company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of actinic keratosis (AK), pre-cancerous skin lesions, which may progress to invasive skin cancers. Additionally, Biofrontera conducts clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit [www.biofrontera-us.com](https://www.biofrontera-us.com) and follow Biofrontera on LinkedIn and X.
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet